JP7231543B2 - 心不全および心臓虚血再灌流障害の治療 - Google Patents

心不全および心臓虚血再灌流障害の治療 Download PDF

Info

Publication number
JP7231543B2
JP7231543B2 JP2019528748A JP2019528748A JP7231543B2 JP 7231543 B2 JP7231543 B2 JP 7231543B2 JP 2019528748 A JP2019528748 A JP 2019528748A JP 2019528748 A JP2019528748 A JP 2019528748A JP 7231543 B2 JP7231543 B2 JP 7231543B2
Authority
JP
Japan
Prior art keywords
shock wave
pharmaceutical composition
inhibitor
dpp
heart failure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019528748A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510616A5 (cg-RX-API-DMAC7.html
JP2020510616A (ja
Inventor
ナロッデン、サロモン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2020510616A publication Critical patent/JP2020510616A/ja
Publication of JP2020510616A5 publication Critical patent/JP2020510616A5/ja
Application granted granted Critical
Publication of JP7231543B2 publication Critical patent/JP7231543B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/22—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for
    • A61B17/225—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for for extracorporeal shock wave lithotripsy [ESWL], e.g. by using ultrasonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14005—Dipeptidyl-peptidase IV (3.4.14.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medical Informatics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
JP2019528748A 2016-11-24 2017-11-17 心不全および心臓虚血再灌流障害の治療 Active JP7231543B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1619861.6A GB201619861D0 (en) 2016-11-24 2016-11-24 Treatments for heart failure and cardiac ischaemic reperfusion injury
GB1619861.6 2016-11-24
PCT/GB2017/053473 WO2018096319A1 (en) 2016-11-24 2017-11-17 Treatments for heart failure and cardiac ischaemic reperfusion injury

Publications (3)

Publication Number Publication Date
JP2020510616A JP2020510616A (ja) 2020-04-09
JP2020510616A5 JP2020510616A5 (cg-RX-API-DMAC7.html) 2021-10-28
JP7231543B2 true JP7231543B2 (ja) 2023-03-01

Family

ID=58073526

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019528748A Active JP7231543B2 (ja) 2016-11-24 2017-11-17 心不全および心臓虚血再灌流障害の治療

Country Status (16)

Country Link
US (1) US20190374623A1 (cg-RX-API-DMAC7.html)
EP (1) EP3544624B1 (cg-RX-API-DMAC7.html)
JP (1) JP7231543B2 (cg-RX-API-DMAC7.html)
KR (1) KR102678011B1 (cg-RX-API-DMAC7.html)
CN (1) CN109996558A (cg-RX-API-DMAC7.html)
AU (1) AU2017365926B2 (cg-RX-API-DMAC7.html)
CA (1) CA3044624A1 (cg-RX-API-DMAC7.html)
ES (1) ES3017482T3 (cg-RX-API-DMAC7.html)
GB (1) GB201619861D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20250664T1 (cg-RX-API-DMAC7.html)
HU (1) HUE071244T2 (cg-RX-API-DMAC7.html)
MY (1) MY200960A (cg-RX-API-DMAC7.html)
PL (1) PL3544624T3 (cg-RX-API-DMAC7.html)
RS (1) RS66778B9 (cg-RX-API-DMAC7.html)
RU (1) RU2767445C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018096319A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023281447A1 (en) * 2021-07-07 2023-01-12 Radius Health, Inc. Methods of treating a cardiovascular ischemic event
US20240122794A1 (en) * 2022-10-12 2024-04-18 Softwave Tissue Regeneration Technologies, Inc. Acoustic shock wave or pressure pulse treatment and methods of use for anti-aging
CN115998768B (zh) * 2023-02-07 2024-01-30 西南医科大学 M2型巨噬细胞外泌体在制备治疗心肌缺血再灌注损伤药物中的应用
CN117257785A (zh) * 2023-11-09 2023-12-22 新疆医科大学 没食子酸及其衍生物在制备预防和/或治疗心肌损伤药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090297470A1 (en) 2006-04-19 2009-12-03 Ludwig-Maximilians-Universitat Munchen Remedies for ischemia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007118680A2 (en) * 2006-04-19 2007-10-25 Ludwig-Maximilians-Universität München Remedies for ischemia
KR20110135411A (ko) * 2009-03-27 2011-12-16 브리스톨-마이어스 스큅 컴퍼니 Dpp-iv 억제제로 주요 유해 심장혈관 이벤트를 예방하는 방법
US9526728B2 (en) * 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090297470A1 (en) 2006-04-19 2009-12-03 Ludwig-Maximilians-Universitat Munchen Remedies for ischemia

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Ihara, Madoka et al.,American Journal of Physiology: Heart and Circulatory Physiology,2015年05月15日,Vol. 308, No. 10,pp. H1287-H1297
Ito, Yoshitaka et al.,Coronary Artery Disease,2010年08月,Vol. 21, No.5,pp. 304-311
J. Vainer et al.,Netherlands Heart Journal,2016年03月02日,Vol. 24, No.5,pp.343-349

Also Published As

Publication number Publication date
KR20190100199A (ko) 2019-08-28
PL3544624T4 (pl) 2025-11-03
US20190374623A1 (en) 2019-12-12
WO2018096319A1 (en) 2018-05-31
RU2019119110A (ru) 2020-12-24
EP3544624C0 (en) 2025-02-12
RU2019119110A3 (cg-RX-API-DMAC7.html) 2021-08-30
GB201619861D0 (en) 2017-01-11
CA3044624A1 (en) 2018-05-31
KR102678011B1 (ko) 2024-06-25
EP3544624B1 (en) 2025-02-12
RU2767445C2 (ru) 2022-03-17
HUE071244T2 (hu) 2025-07-28
EP3544624A1 (en) 2019-10-02
CN109996558A (zh) 2019-07-09
HRP20250664T1 (hr) 2025-10-24
RS66778B9 (sr) 2025-08-29
MY200960A (en) 2024-01-26
PL3544624T3 (pl) 2025-11-03
JP2020510616A (ja) 2020-04-09
AU2017365926A1 (en) 2019-07-04
ES3017482T3 (en) 2025-05-13
AU2017365926B2 (en) 2025-06-05
RS66778B1 (sr) 2025-06-30

Similar Documents

Publication Publication Date Title
Samuel et al. Relaxin remodels fibrotic healing following myocardial infarction
Hiasa et al. Bone marrow mononuclear cell therapy limits myocardial infarct size through vascular endothelial growth factor
US20090297470A1 (en) Remedies for ischemia
US10864229B2 (en) Use of nitrite salts in chronic ischemia
KR102678011B1 (ko) 심부전 및 심장 허혈성 재관류 손상 치료
JP2014533697A (ja) デフェリプロンを用いた処置方法
ES2848348T3 (es) Composiciones y métodos de tratamiento con ifetroban de la fibrosis cardíaca
Rajani et al. Post-infarct morphine treatment mitigates left ventricular remodeling and dysfunction in a rat model of ischemia-reperfusion
Pourtaji et al. Application of G-CSF in congestive heart failure treatment
D’Amario et al. Granulocyte colony-stimulating factor for the treatment of cardiovascular diseases: An update with a critical appraisal
Luo et al. Emerging therapies: Potential roles of SGLT2 inhibitors in the management of pulmonary hypertension
Kanemitsu et al. Insulin-like growth factor-1 enhances the efficacy of myoblast transplantation with its multiple functions in the chronic myocardial infarction rat model
de Freitas et al. Effects of exercise training and stem cell therapy on the left ventricle of infarcted rats
Shudo et al. Myocardial layer-specific effect of myoblast cell-sheet implantation evaluated by tissue strain imaging
JP2019507174A (ja) 心血管疾患におけるリラグルチド
CN1406132A (zh) 处理或抑制细胞损伤或细胞死亡的方法
Blum Endoethelial progenitor cells are affected by medications and estrogen
Engelmann et al. G-CSF in patients suffering from late revascularized ST elevation myocardial infarction: analysis on the timing of G-CSF administration
JP2018502055A (ja) マクロファージ炎症性タンパク質−1β抑制剤の使用方法
Ripa et al. Safety of Bone Marrow Stem Cell Mobilization Induced by Granulocyte-Colony Stimulating Factor: 30 Days’ Blinded Clinical Results from the Stem Cells in Myocardial Infarction (STEMMI) Trial
Kawaguchi et al. The effect of telmisartan on the ventricular systolic function in dogs with experimental supraventricular tachyarrhythmia
Mitsi et al. Early, intracoronary growth hormone administration attenuates ventricular remodeling in a porcine model of myocardial infarction
TWI774059B (zh) Cxcl5中和抗體用於製備預防或治療周邊動脈阻塞疾病的藥物的用途
Shikraki et al. PS-B03-4: A NOVEL SOLUBLE EPOXIDE HYDROLASE VACCINE PROTECTS MURINE CARDIAC MUSCLE AGAINST MYOCARDIAL INFARCTION
Pastormerlo et al. P4025 Sympathetic renal denervation after acute myocardial infarction results in increased myocardial salvage in pigs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210129

A917 Reason for reinstatement of right to file examination request

Free format text: JAPANESE INTERMEDIATE CODE: A917

Effective date: 20210129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210907

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230123

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230207

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230216

R150 Certificate of patent or registration of utility model

Ref document number: 7231543

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150